Technical University of Munich spin-out ImevaX partners with Project Pharmaceuticals on stomach pain.

ImevaX, a biotech spin-out of the Technical University of Munich, has announced plans to partner with Germany-based Project Pharmaceuticals on tackling stomach pain caused by bacterium.

Specifically, the two companies are targeting a microaerophilic bacterium known as Helicobacter pylori. While up to 85% of people infected with H. pylori never experience complications, it has been linked to gastric ulcers, chronic gastritis, and stomach cancer.

The agreement will seek to develop IMX101, a multicomponent vaccine against the bacterium. 

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?